Genmab

Genmab appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as a company that can have very valuable products while still depending on larger partners for commercialization. The source uses Genmab to show why product success alone does not automatically equal full [[GlobalPharmaCommercialization|global pharma commercialization]].

Connections

• BioTech To BioPharm Transition - boundary between product development and full commercialization.
• Global Pharma Commercialization - capability Genmab helps clarify by contrast.
• Biotech License-Out Arbitrage - adjacent value-capture concern when commercial rights sit with larger partners.